Novartis shares slipped 0.1% premarket Thursday despite raising peak sales targets for cancer drugs Kisqali and Scemblix and extending its mid-term growth outlook through 2030. The company highlighted a strong pipeline, upcoming clinical readouts, US expansion plans, and ongoing restructuring efforts, including job cuts, as drivers of its long-term confidence.